News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Amgen Develops Six Cancer Drugs as Anemia Decline Hurts Revenue
April 11, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
April 11 (Bloomberg) -- Amgen Inc., the world's largest biotechnology company by sales, is developing six cancer drugs to help recover from a decline in its anemia products.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Amgen
MORE ON THIS TOPIC
Rare diseases
BioMarin bounces back as Voxzogo performs ‘bigger than expected’ in new indication
May 21, 2026
·
2 min read
·
Tristan Manalac
Insights
Inside Germany’s biotech capital infrastructure and innovation engine
May 21, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Deals
Lilly and Engage Bio tie the knot with $202M acquisition
May 20, 2026
·
2 min read
·
Gabrielle Masson
Drug Development
Beam one-ups Wave as both show promise of genetic editing for AATD
May 20, 2026
·
2 min read
·
Tristan Manalac
